A. Haque

发表

Characterisation of a Composite Exonic Regulatory Element of Splicing (CERES) in CFTR Exon 12: Functional Properties and Evolutionary Constraints

A. Haque, 2010 .

ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)

R. Larson, R. Clark, H. Kantarjian, 2010 .

A Phase II Study of Nilotinib A Novel Tyrosine Kinase Inhibitor Administered to Imatinib-Resistant or Intolerant Patients with Chronic Myelogenous Leukemia (CML) in Accelerated Phase (AP).

M. Baccarani, K. Bhalla, H. Kantarjian, 2006 .

Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study.

M. Baccarani, H. Kantarjian, J. Cortes, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nilotinib in Chronic Myeloid Leukemia Patients in Accelerated Phase (CML-AP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study

M. Baccarani, H. Kantarjian, J. Cortes, 2008 .

Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib.

Martin C. Müller, J. Radich, H. Kantarjian, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CMLCP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study.

R. Larson, M. Baccarani, K. Bhalla, 2008 .

Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.

Martin C. Müller, L. Beppu, J. Radich, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Minimal Cross-Intolerance Between Nilotinib and Imatinib in Patients with Imatinib-Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) or Accelerated Phase (CML-AP)

M. Baccarani, H. Kantarjian, J. Cortes, 2008 .

Nilotinib Demonstrates Superior Efficacy Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: Results From the International Randomized Phase III ENESTnd Trial

R. Larson, R. Clark, H. Kantarjian, 2009 .

Nilotinib Efficacy According to Baseline BCR-ABL Mutations in Patients with Imatinib-Resistant Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Martin C. Müller, J. Radich, G. Martinelli, 2008 .

A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP)

R. Larson, H. Kantarjian, F. Giles, 2007 .

A case report of a successfully treated patient of granulomatosis with polyangitis and diabetes mellitus

A. Haque, T. Samad, Tasnova Mahin, 2022, BIRDEM Medical Journal.

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Ricardo Pasquini, Giuseppe Saglio, Andreas Hochhaus, 2010, The New England journal of medicine.

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.

K. Bhalla, H. Kantarjian, F. Giles, 2007, Blood.

Clinical Profile of Acute Pancreatitis in Children in a Tertiary Level Hospital of Bangladesh

A. Haque, A. Karim, Wahiduzzaman Mazumder, 2017 .

Functional properties and evolutionary splicing constraints on a composite exonic regulatory element of splicing in CFTR exon 12

E. Buratti, F. Baralle, A. Haque, 2009, Nucleic acids research.

Nilotinib in Patients (pts) with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib.

R. Larson, M. Baccarani, H. Kantarjian, 2007 .

Identification of TNF-Þ-308G/A (rsl800629) polymorphism in Bangladeshi population related to type-2 diabetes

A. Haque, M. Hasan, B. Basak, 2019, Journal of Applied Biology & Biotechnology.

Nilotinib Is Highly Active and Safe in Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Patients with Imatinib-Resistance or Intolerance.

M. Baccarani, K. Bhalla, H. Kantarjian, 2007 .

Mutation detection sensitivity of high resolution melting in clinical samples: a comparative study between formamide and dimethyl sulfoxide

A. Haque, Hasan, Dipa Roy, 2019, Journal of Advanced Biotechnology and Experimental Therapeutics.

Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukemia in chronic phase (CML-CP): Updated phase II results

K. Bhalla, H. Kantarjian, F. Giles, 2008 .

Nilotinib in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib-resistance or -intolerance: Update of a phase II study

R. Larson, H. Kantarjian, J. Cortes, 2008 .

Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myelogenous leukemia (CML) in chronic phase (CP) or accelerated phase (AP)

K. Bhalla, H. Kantarjian, J. Cortes, 2008 .

Nilotinib in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib

R. Larson, H. Kantarjian, F. Giles, 2008 .

Responses and Disease Progression in CML-CP Patients Treated with Nilotinib after Imatinib Failure Appear To Be Affected by the BCR-ABL Mutation Status and Types.

J. Radich, G. Martinelli, G. Saglio, 2007 .

Nilotinib Is Associated with Minimal Cross Intolerance to Imatinib in Patients with Imatinib-Intolerant Philadelphia-Positive (Ph+) Chronic Myelogenous Leukemia (CML) in Either Chronic Phase (CP) or Accelerated Phase (AP).

M. Baccarani, K. Bhalla, H. Kantarjian, 2007 .

Response and Outcomes to Nilotinib at 24 Months in Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) and Accelerated Phase (CML-AP) with and without BCR-ABL Mutations.

Martin C. Müller, L. Beppu, J. Radich, 2009 .

Nilotinib in Patients (pts) with Philadelphia Chromosome-Positive (Ph+) Chronic Myelogenous Leukemia in Blast Crisis (CML-BC) Who Are Resistant or Intolerant to Imatinib.

R. Larson, M. Baccarani, H. Kantarjian, 2007 .

Nilotinib Therapy after Dasatinib Failure in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP), Accelerated Phase (AP) or Blast Crisis (BC).

K. Bhalla, H. Kantarjian, F. Giles, 2007 .

Molecular Response at 3 Months On Nilotinib Therapy Predicts Response and Long-Term Outcomes in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP).

Martin C. Müller, L. Beppu, J. Radich, 2009 .

RESCUE OF REFRACTORY SPLICING OF CFTR EXON 12 PATHOLOGICAL MUTATIONS G576A/G48C USING ANTISENSE OLIGONUCLEOTIDES

A. Haque, 2011 .

Frequency of Celiac Disease in Children Presented with Liver Disease at a Tertiary Care Center

A. Haque, A. Karim, Nadira Mosabbir, 2017 .

Efficacy and Tolerability of Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) Who Failed Prior Imatinib and Dasatinib Therapy: Updated Results of a Phase 2 Study

K. Bhalla, H. Kantarjian, F. Giles, 2008 .

Nilotinib in chronic myelogenous leukemia patients who failed prior imatinib and dasatinib therapy: Updated results of an open-label phase II study

K. Bhalla, H. Kantarjian, F. Giles, 2008 .

Nilotinib Lowers the Incidence of BCR-ABL Mutations and Improves the Molecular Response Kinetics Compared with Imatinib in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia (CML).

I. Flinn, R. Larson, H. Kantarjian, 2010 .

Correlation of Clinical Response to Nilotinib with BCR-ABL Mutation Status in Advanced Phase Chronic Myelogenous Leukemia (CML-AP) Patients with Imatinib-Resistance or Intolerance.

J. Radich, G. Martinelli, G. Saglio, 2007 .

K. Bhalla, H. Kantarjian, F. Giles, 2007, Blood.

Prevalence of single-nucleotide polymorphism (-308G>A) in the TNF-α promoter region correlates coronary heart disease among type-2 diabetic patients from the northern region of Bangladesh

A. Haque, M. Hasan, A. Reza, 2020 .